US Edition
Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin
- On June 20, 2025, Vertex hosted an investor event in Chicago presenting positive one-year data on zimislecel for type 1 diabetes patients with severe hypoglycemia.
- The event followed results from 12 patients who each received a single full dose infusion of zimislecel and were monitored for at least one year as of October 2024.
- All 12 patients met ADA targets of HbA1c below 7% and over 70% time in range, with 10 patients becoming insulin free and complete elimination of severe hypoglycemic events.
- Michael R. Rickels called it remarkable that all patients reached consensus glycemic control targets and Carmen Bozic highlighted the durability and transformative potential of zimislecel.
- These results suggest zimislecel could transform treatment for type 1 diabetes complicated by severe hypoglycemia, while it remains investigational and unapproved globally.
71 Articles
71 Articles
Encapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes
Clinical studies on the treatment of type 1 diabetes with device-encapsulated pancreatic precursor cells derived from human embryonic stem cells found that insulin output was insufficient for clinical benefit. We are conducting a phase 1/2, open-label, multicenter trial aimed at optimizing cell engraftment (ClinicalTrials.gov identifier: NCT03163511 ). Here we report interim, 1-year outcomes in one study group that received 2–3-fold higher cell …
Most of a small group of patients who received a cell-based infusion did not need more than insulin, but the medicine may not be suitable for those with type 1 more controlled diabetes A single infusion of a cell-based therapy may have treated 10 out of 12 people with the most serious type of diabetes 1. One year later, these 10 patients no longer need insulin. The other two need much lower doses. The experimental treatment called zimislecell an…
Coverage Details
Bias Distribution
- 94% of the sources are Center
To view factuality data please Upgrade to Premium
